Beta

Actinium pharmaceuticals, inc.ATNM.US Overview

US StockHealthcare
(No presentation for ATNM)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

ATNM AI Insights

ATNM Overall Performance

ATNM AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ATNM Recent Performance

-1.65%

Actinium pharmaceuticals, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

ATNM PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check ATNM's Trend

ATNM Key Information

ATNM Valuation Metrics

ATNM Profile

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Price of ATNM

ATNM FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ATNM Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.08
PE Ratio (TTM)
-
Forward PE
6.84
PS Ratio (TTM)
446.22
PB Ratio
5.25
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-37652.22%
Revenue Growth (YoY)
11.11%
Profit Growth (YoY)
11.11%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.08
PE Ratio (TTM)
-
Forward PE
6.84
PS Ratio (TTM)
446.22
PB Ratio
5.25
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-37652.22%
Revenue Growth (YoY)
11.11%
Profit Growth (YoY)
11.11%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is ATNM's latest earnings report released?

    The most recent financial report for Actinium pharmaceuticals, inc. (ATNM) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ATNM's short-term business performance and financial health. For the latest updates on ATNM's earnings releases, visit this page regularly.

  • How much debt does ATNM have?

    As of the end of the reporting period, Actinium pharmaceuticals, inc. (ATNM) had total debt of 1.69M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ATNM have?

    At the end of the period, Actinium pharmaceuticals, inc. (ATNM) held Total Cash and Cash Equivalents of 48M, accounting for 0.93 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ATNM's EPS continuing to grow?

    According to the past four quarterly reports, Actinium pharmaceuticals, inc. (ATNM)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.19. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ATNM?

    Actinium pharmaceuticals, inc. (ATNM)'s Free Cash Flow (FCF) for the period is -5.39M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 6.23% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ATNM?

    The latest valuation data shows Actinium pharmaceuticals, inc. (ATNM) has a Price-To-Earnings (PE) ratio of -0.92 and a Price/Earnings-To-Growth (PEG) ratio of -0.1. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.